→ An FDA Approved drug for the treatment of Type 2 diabetes → An oral agent used mainly to regulate postprandial glucose in patients with T2DM → A viable choice for use as initial therapy in patients with newly diagnosed T2DM1 → Effective, safe, and well tolerated and is associated with a low incidence of gastrointestinal adverse effects1 → Acarbose with metformin results in greater reductions of HbA1c, fasting blood glucose and post-prandial glucose than either agent alone